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Abstract
Introduction. Depression is a major public health problem. Magnesium (Mg2+) is involved in many metabolic processes as 
an activator of over 300 different enzymes. For the last 60 years lithium (Li+) compounds have been used in psychiatry. Li+ 
salts are regarded as the first choice medicine in the treatment of affective disorders and are also applied as an adjuvant 
intensifying the therapy in drug-resistant depression patients.
Objective. The objective of the study was an analysis of the relationship between the levels of magnesium, lithium, and 
education and place of residence of patients hospitalized due to depression.
Material and methods. Patients with bipolar affective disorders undergoing lithium therapy during their stay in the 
Department of Psychiatry at the Medical University in Lublin were examined. Patients were divided into three groups 
according to education level and were also analyzed according to place of residence.
Results. In the group of patients in the study, a significantly lower level of magnesium was found (p=0.02) in blood plasma 
of patients with secondary education level, compared to those who had elementary education. There was also a significantly 
higher level of magnesium (p=0.01) in blood plasma of patients who lived in urban areas, compared to rural inhabitants. No 
statistically significant differences were noted between lithium level in plasma, and the patients’ place of residence (p=0.34).
Conclusion. Significantly higher plasma magnesium levels were observed among city than village inhabitants, there was 
also a relationship between type of education and magnesium level in blood plasma of the patients in the study. Further 
studies including larger groups of patients should be performed to enable a final conclusion.
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IntROduCtIOn
Depression is a major public health problem [1]; however, 
to date, the pathogenesis of depressive disorders has not been 
clarified [1]. Research on the subject revealed relationships 
with disturbances of neurotransmission [2]. Serotonin and 
catecholamine neurotransmission have been found to be 
altered in depression [3, 4]. The results of studies suggest, 
however, that the pathogenesis of depression is more 
complicated [1], and that amino-acidergic transmission, as 
well as selected bioelements (e.g. zinc), can also play a role 
[5]. Some studies have also revealed that magnesium may 
affect NMDA receptor functions, as well as other systems 
involved in the pathophysiology of depression, which may 
suggest that this element is involved in the pathogenesis of 
the disease [6, 7].
Magnesium (Mg2+) is the second most abundant 
intracellular cation and the fourth most abundant one 
overall in the human organism. As an activator of over 300 
different enzymes it is involved in many metabolic processes. 
Mg2+ affects the nervous system through its actions on the 
release and metabolism of neurotransmitters and other 
mechanisms [8].
The ability of magnesium to suppress hippocampal 
kindling, to decrease the release of adrenocorticotrophic 
hormone (ACTH), and to affect adrenocortical sensitivity 
to ACTH has been demonstrated [6]. The involvement of 
magnesium in the functioning of the central nervous system 
may be mediated via the N-methyl-D-aspartate-antagonistic, 
γ-aminobutyric acid agonistic, or the angiotensin II-
antagonistic property of this ion [6, 9]. Magnesium also 
appears to have GABA(A)-agonistic or NMDA-antagonistic 
effects on sleep and nocturnal hormonal secretion, and hence 
it may exert a powerful effect on controlling the symptoms 
of depression and in preventing seizures [6, 10].
Furthermore, Mg2+ exerts a direct effect on the function 
of the transport protein P-gp (p-glycoprotein) at the level 
of the blood-brain barrier, possibly influencing the access 
of corticosteroids to the brain [6, 9]. Magnesium also 
dampens the calcium ion-dependent protein kinase related 
neurotransmission and stimulates the Na–K-ATPase. All 
these systems have been reported to be involved in the 
pathophysiology of depression [6]. Because of the importance 
of Mg2+ for monoamine neurotransmitter synthesis and 
receptor binding, it has behaviour-altering effects. The 
anti-depressant-like effect of magnesium is dependent on 
its interaction with the serotonergic, noradrenergic and 
dopaminergic receptors [9].
For the last 60 years, lithium (Li+) compounds have been 
used in psychiatry [11]. Li+ salts are regarded as the first choice 
medication in the treatment of affective disorders [12] and 
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are also applied as an adjuvant intensifying the therapy in 
drug-resistant depression patients [13]. Interactions between 
lithium and magnesium have been described. Lithium 
and  magnesium cations have similar physicochemical 
properties, and competition for binding sites in cellular 
components between these elements may be a part of Li+ 
action [11, 14]. Studies on the mood-stabilizing influence 
of Li+ have revealed that lithium may reverse some effects 
caused by magnesium [15]. Furthermore, lithium has been 
reported to influence homeostasis of both macro- and micro-
elements [16, 17, 18].
The objective of the study was an analysis of the 
relationship between the levels of magnesium, lithium, and 
education and  place of residence of patients hospitalized 
due to depression.
MAteRIAls And MethOds
Study protocol and patient distribution. The presented 
study was approved by the Committee for Bioethics at the 
Medical University in Lublin, and informed consents were 
obtained from all patients. Patients with bipolar affective 
disorders undergoing lithium therapy during their stay in the 
Department of Psychiatry at the Medical University in Lublin 
were examined. The criteria for enrolment of patients in the 
study were as follows: at least a two-year manic-depressive 
disorder of type I or II, current hospitalization due to a 
depressive episode without psychotic symptoms, absence of 
suicidal tendencies, no addiction to psychoactive substances, 
including benzodiazepines, no indication of the organic 
CNS injury, and aged over 18. Criteria for exclusion from the 
study were: pregnancy, breast-feeding, mental retardation, 
dementia, addiction to psychoactive substances, alcohol 
addiction, aged below 18, lack of consent to participate in the 
study, the presence of psychotic symptoms during the current 
hospitalization, concomitant chronic somatic disease. All 
of the patients enrolled in the study met criteria for a mild 
depressive episode of a moderate or severe degree without 
psychotic symptoms during the course of bipolar affective 
disorder according to the criteria for classification of mental 
and behavioral disorders.
On admission, all patients were prescribed lithium and 
the administered doses during the research in individual 
patients ranged from 500 mg-1,250 mg per day. Patients also 
received: sodium valproate at a dose of 800-1,500 mg/day, 
lamotrigine at a dose of 100-200 mg/day, carbamazepine 
at a dose of 600-800 mg/day, quetiapine at a dose of 250-
400 mg/day, olanzapine at a dose of 10-20 mg/day and 
antidepressants: sertraline (50-100 mg/day), citalopram 
(20 mg/day), venlafaxine (150 mg/day).
None of the patients had ever received lithium treatment 
before the study. Evaluation of lithium and magnesium 
concentrations was made in the last (eighth) week of 
treatment.
Patients were divided into three groups according to 
education level: elementary, secondary, and university. 
Changes in Li+ and Mg2+ were also analyzed according to 
place of residence – urban and rural. Venous blood samples 
(10 ml) were collected in heparin test tubes, and plasma 
was separated by centrifugation at 3,000 x g for 15 min. 
for measurement of magnesium and lithium. The obtained 
plasma was stored at the temperature of -20oC.
Mineral analysis. Total magnesium plasma concentrations 
were determined by the reaction with xylidyl blue (diagnostic 
set Liquick Cor-MG 60, manufacturer P.Z. CORMAY, 
Łomianki, Poland), using the colorimetric method. Wave 
length was 520 nm. The assays were carried out with the use 
of a SPECORD M40 (Zeiss Jena) spectrophotometer.
Lithium plasma concentrations were determined using 
ion-selective electrode Integrat 400 (Roche Diagnostics, 
Basle, Switzerland).
Statistical analysis. Mean and standard deviations (SD) 
were calculated for parametric data. Categorical variables 
were compared using the χ2 and Fisher exact tests, and 
the Yates correction applied. The unpaired Student’s t-test 
was used to analyse variables with a normal distribution. 
Non-parametric data were statistically analysed using the 
Wilcoxon signed-rank test and Kruskal–Wallis ANOVA test 
for initial detection of differences. P < 0.05 was considered 
to be statistically significant. The power of all statistical tests 
was determined by G*Power software (1 – β).
Results
Sixty patients with bipolar affective disorder who were 
treated during the period from October 2010 – March 2011 were 
qualified for the study. A further 23 patients were excluded for 
the following reasons: withdrawal of consent to participate in 
the study, a suicidal attempt during hospitalization, discharge 
from the department upon request. Finally, 37 patients with 
bipolar affective disease were examined (Tab. 1), all of them 
were admitted to the Department of Psychiatry at the Medical 
University in Lublin due to an episode of depression, and 
hospitalized for 8 weeks. According to their education level, 
seven patients had basic (18.92%), 11 – secondary (29.73%) 
and 19 – university education (51.35%). According to place 
oe residence, 15 patients were from villages (40.54%), and 22 
were from towns (59.46%).
table 1. Characteristics of patients in the study
Characteristics of patients Total
Education
Elementary 7 (18.92%)







Plasma lithium concentrations were generally included into 
the recommended therapeutic range which was established 
as 0.6-1.0 mmol/l. In the group of patients in the study, a 
significantly lower level of magnesium was found (p=0.02) 
in blood plasma of patients with secondary education level, 
compared to those who had basic education. However, no 
statistically significant differences were noted between 
the magnesium level in blood plasma of patients who had 
university education, compared to those with basic and 
secondary education levels (p=0.23 and p=0.10, respectively) 
(Fig. 1). In addition, own studies showed a significantly higher 
level of magnesium (p=0.01) in blood plasma of patients 
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who lived in towns, compared to villages (Fig. 2). This may 
be due to the percentages of respondents with secondary 
and basic education level living in the country- 54% and 
46%, respectively, whereas in the towns as many as 86% of 
patients possessed university education, while only 14% of 
respondents possessed secondary education. While analyzing 
the level of lithium in blood plasma of patients according 
to education, no statistically significant differences were 
found between respondents who had basic and secondary 
school education (p=0.72), and university education level 
(p=0.20), nor between respondents with secondary school 
and university education (p=0.58), (Fig. 3). No statistically 
significant differences were noted between lithium level in 
plasma, and the patients’ place of residence (p=0.34) (Fig. 4).
dIsCussIOn
Affective disorders afflict 10% of the population [19], 
characterized by alternate occurrences of depressive and 
manic episodes (affective bipolar disease), or solely depressive 
episodes (affective unipolar disorder). These are chronic and 
recurrent disorders associated with high premature death 
rates in relation with a high risk of committing a suicidal 
attempt, and a higher exposure to the development of somatic 
diseases, compared to the general population [20]. They also 
lead to serious consequences in the form of limitations in 
family and occupational functioning, and deterioration of 
the quality of life of the patients and their families.
Shealy et al. [21] confirmed that in almost all patients with 
depression there occurred a deficiency of magnesium and 
taurine. A hypothesis was developed that the majority of 
cases of major depression, including postpartum depression, 
may be associated with magnesium deficiency [8]. Reports 
have also been published concerning the magnesium level 
in cerebrospinal fluid in the course of depression. It has been 
confirmed [22] that both the level of 5-HIAA and magnesium in 
cerebrospinal fluid are decreased in individuals suffering from 
depression and suicidal thoughts. Magnesium ion neuronal 
deficits may be induced by stress hormones, an excessive 
supply of calcium, and deficit of magnesium in the diet. 
Dietary magnesium deficiency in combination with an excess 
of calcium and stress may cause other symptoms: excitation, 
anxiety, insomnia, headaches, delirium, hallucinations. A 
decrease in magnesium level is also observed in individuals 
with chronic fatigue syndrome and patients suffering from 
premenstrual tension syndrome – the disorders which may 
be related with a non-specific picture of depression [23, 24].
The results of the presented study show that the level 
of magnesium in blood plasma was significantly lower in 
patients with secondary school education than those who 
had basic education, and significantly lower among village 
than city dwellers.























































































































Figure 2. Changes in plasma magnesium levels according to place of residence
























































































Figure 4. Changes in plasma lithium levels according to place of residence
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Lithium is a medication of the first choice in the preventive 
treatment of bipolar affective disease. It is also used to 
enhance the treatment of drug resistant depression. The 
mechanism of action of the drug is not yet fully understood. 
Lithium influences the transportation of sodium via cellular 
membranes (sodium-potassium ATPase dependant) and 
has an inhibitory effect on a second (connected with 
phosphatidylinositol) transmitter system, probably acting 
in this manner as a stabiliser of inter cellular processes. 
Lithium does not bind with plasmatic proteins and is almost 
entirely excreted by the kidneys.
The side effects of the medication are related to its 
influence on the CNS, as well as the effect of lithium on renal 
transportation of electrolytes, and narrow therapeutic index 
of the medication. This may result in intoxication if medical 
recommendations are not adhered to [25, 26, 27, 28, 29, 30]. 
The most common side effects are: stomach aches, nausea, 
diarrhoea, lack of appetite, polydipsia, polyuria, trembling of 
hands, headaches, sleepiness, and deterioration of memory 
[19, 26, 27]. Lithium may cause weakening of the libido 
and erection disorders in males; however, this undesirable 
symptom of the therapy occurs rarely, and to-date it has not 
been explained to what extent it is affected by accompanying 
symptoms of depression [27, 31].
Pregnancy and the period of breastfeeding are absolute 
contraindications for beginning lithium treatment. The 
lithium ion penetrates through the placenta and in the 
plasma of the foetus reaches the same level as in the plasma 
of the mother [19, 32]. Pinelli et al. [32] carried out a review 
of reports from literature concerning the effect of lithium 
on the risk of prenatal complications. The following disorders 
most frequently occur in mothers treated with lithium: heart 
defects, primarily Ebstein’s syndrome, cardiac arrhythmia, 
lower level of glucose in blood, reduced values of arterial 
pressure, respiratory failure, cyanosis, coma, thyroid 
function disorders, and hyperbilirubinemia. The majority 
of symptoms of the toxic effect of lithium on the foetus are 
transitory and exert no effect of further childhood [32].
Considering the indications and contraindications 
of lithium treatment and the occurrence of undesirable 
symptoms, the criteria for the enrolment of patients 
into own  studies therefore did not cover: pregnancy, 
breastfeeding, mental retardation, dementia, addiction to 
psychoactive substances, alcohol addiction, lack of consent 
to participate in the study, presence of psychotic symptoms 
during the  current hospitalization, concomitant chronic 
somatic disease.
While analyzing the level of lithium in blood plasma of 
patients according to education level and place of residence, 
no statistically significant differences were noted in the group 
of patients examined. However, further studies including 
larger groups of patients should be performed to enable a 
final conclusion.
COnClusIOns
1. Significantly higher levels of magnesium in blood plasma 
were observed among city than village dwellers.
2. A relationship was confirmed between the education level 
and level of magnesium in blood plasma of the patients 
examined. The lowest magnesium level was noted among 
patients with secondary school education.
3. No relationship was observed between the place of 
residence and the level of lithium in blood plasma in the 
group of patients in the study. The level of lithium in 
blood remained on a comparable level, irrespective of the 
patients’ education.
4. Further studies including larger groups of patients should 
be performed to draw a final conclusion.
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